Harrow to acquire global rights to TYRVAYA nasal spray from Viatris

Harrow announced on August 6, 2026 that it signed a definitive agreement to acquire global rights to TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris Inc. Harrow entered a definitive agreement to acquire TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease, from Viatris.¹ TYRVAYA is a cholinergic agonist for treating the signs and symptoms of dry eye disease and is currently approved in the U.S., China, and Taiwan, with marketing applications pending elsewhere.¹

Under the terms disclosed in the 8-K, dated August 3, 2026, the acquired assets include the drug's regulatory approvals, intellectual property, technology, inventory and related contracts, and Harrow will take on certain associated liabilities, as described in the agreement's asset transfer terms. Harrow will pay Viatris $30,000,000 in cash at closing and has agreed to pay up to an additional $70,000,000 tied to net sales thresholds for TYRVAYA in specified future years.¹ Harrow expects to fund the closing payment with cash on hand.¹ The purchase price is subject to a customary post-closing adjustment based on transferred net working capital.¹

The company said it expects the transaction to close in the second half of 2026, though it cautioned that completion within that window, or at all, is not guaranteed, per the filing's standard forward-looking language. The companies will also enter ancillary agreements at closing, including a transition services agreement.¹

On the clinical side, TYRVAYA differs from Harrow's existing VEVYE (cyclosporine ophthalmic solution) 0.1% by working through a separate pathway. Its label reports sneezing as the most common adverse reaction, occurring in 82% of patients, with cough, throat irritation, and nasal instillation-site irritation reported in 5 to 16% of patients.¹ Harrow said it intends to file the full purchase agreement as an exhibit to its Form 10-Q for the quarter ending September 30, 2026.¹